Two Sigma Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,600
Closed -$277K 3405
2024
Q2
$277K Sell
2,600
-12,200
-82% -$1.22M ﹤0.01% 2062
2024
Q1
$1.43M Buy
14,800
+7,200
+95% +$738K 0.01% 932
2023
Q4
$767K Buy
7,600
+100
+1% +$9.65K 0.01% 1220
2023
Q3
$764K Buy
7,500
+100
+1% +$10.2K 0.01% 1225
2023
Q2
$747K Buy
+7,400
New +$740K 0.01% 1166
2022
Q2
Sell
-4,000
Closed -$351K 2665
2022
Q1
$351K Buy
+4,000
New +$346K 0.01% 1274
2021
Q1
Sell
-6,600
Closed -$623K 1479
2020
Q4
$623K Sell
6,600
-2,500
-27% -$218K 0.01% 591
2020
Q3
$791K Buy
9,100
+600
+7% +$52K 0.02% 421
2020
Q2
$742K Buy
8,500
+3,600
+73% +$311K 0.02% 485
2020
Q1
$404K Sell
4,900
-27,500
-85% -$2.45M 0.01% 704
2019
Q4
$3.07M Sell
32,400
-3,400
-9% -$305K 0.02% 568
2019
Q3
$3.11M Sell
35,800
-8,700
-20% -$781K 0.03% 432
2019
Q2
$4.06M Buy
+44,500
New +$3.77M 0.04% 276
2018
Q4
Sell
-55,242
Closed -$4.26M 2619
2018
Q3
$4.26M Sell
55,242
-45,533
-45% -$3.37M 0.03% 422
2018
Q2
$6.82M Buy
100,775
+58,255
+137% +$4.02M 0.03% 388
2018
Q1
$3.08M Buy
42,520
+36,159
+568% +$2.75M 0.02% 668
2017
Q4
$479K Buy
+6,361
New +$480K 0.01% 726

Other funds holding NVS

Two Sigma Securities's NVS Position: Q3 2025 in Review

Two Sigma Securities sold out of Novartis (NVS) in Q3 2025, closing a stake of 2,808 shares — an estimated $340K sold.

Two Sigma Securities first reported a position in NVS in Q1 2017 and held it in 17 quarters. The position peaked at $10.7M in Q1 2018. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • Two Sigma Securities reported no remaining Novartis position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 2,808 Novartis shares in Q3 2025, an estimated $340K.
  • Two Sigma Securities first reported a position in Novartis in Q1 2017 and held it in 17 quarters.
  • Two Sigma Securities's Novartis position peaked at $10.7M in Q1 2018.
  • 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.